CRPC

ASCO Guideline Update Recommends Androgen-Deprivation Therapy, Somatic Genetic Testing for mCRPC

Radium 223 is recommended for patients with symptomatic bone-only disease.

Latest News

FDA Approves 177Lu Vipivotide Tetraxetan for PSMA+ mCRPC Treatment Before Chemotherapy

Emily MenendezCRPC | March 31, 2025

177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Emily MenendezRLT | March 7, 2025

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MDCRPC | March 5, 2025

Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.

Mevrometostat With Enzalutamide: Better Outcomes Compared With Enzalutamide Monotherapy for mCRPC

Emily MenendezCRPC | February 25, 2025

The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.

Final TALAPRO-2 Analysis: Talazoparib Plus Enzalutamide Significantly Improves Survival in HRR-Deficient mCRPC

Brandon TwyfordCRPC | February 21, 2025

Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.

Real-World Outcomes of Lu-PSMA-617 in mCRPC

Jordan Ciuro, MDCRPC | February 14, 2025

New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer

Localized

nmCRPC

mHSPC

RLT

Prostate Cancer Diagnostics

Prostate Cancer

Localized

nmCRPC

mHSPC

Conference Coverage

Dr. David Canes on WellPrept - Boosting Patient Education and Improving Care

David Canes, MDUrothelial Carcinoma | May 7, 2025

Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.

Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology

Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025

Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.

ctDNA in GU Oncology: History, Current Studies, and Benefits

John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025

John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.

cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?

Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025

Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.

Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection

Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025

Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.

Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension

Joseph Cheaib, MDnccRCC | May 5, 2025

Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.